OLAPARIB | ASTRAZENECA | ||
50MG | |||
No | No | ||
2031-Aug-04 | 2019-Dec-19 | ||
2021-Dec-19 | None | ||
None | No | ||
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. |
0 | 0 | 0 |
Total Other Developers | None |
---|
Drugs with Suitability | No |
---|
50MG | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
No | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com